By the Peptevity Research Desk — vendor-neutral, evidence-graded. Scientific review: independent reviewer pending — how our review works.

BPC-157: An Evidence-Graded Monograph

Direct answer

BPC-157 (body protection compound 157) is a synthetic 15-amino-acid peptide based on a partial sequence reported in human gastric juice, first described in 1993 by Predrag Sikirić and colleagues at the University of Zagreb (Sikirić et al., PMC7096228). It is studied as a cytoprotective agent, with proposed actions on the nitric oxide system, angiogenesis, and growth-factor signaling. The headline reputation — fast healing of tendon, ligament, muscle, bone, and gut tissue — rests overwhelmingly on animal studies, mostly in rats (Grade C) (PMC8275860). A 2025 narrative review found only three small human pilot studies and no randomized controlled trials in humans (PMC12446177). BPC-157 is not FDA-approved; the FDA placed it in 503A Category 2 in 2023 (citing immunogenicity and impurity concerns), removed it from that list in April 2026 (removal is not approval), and a compounding advisory committee reviews it on July 23–24, 2026. It is banned by WADA.

What BPC-157 is

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It corresponds to a partial sequence of "body protection compound" (BPC), a protein reported in mammalian gastric juice, and was first described in the early 1990s — specifically a 1993 publication identifying "a new gastric juice peptide, BPC" — by Predrag Sikirić, Sven Seiwerth, and colleagues at the University of Zagreb (Sikirić et al., PMC7096228). The material studied today is produced by chemical synthesis, not isolated from stomach fluid.

One property that made it attractive as a research molecule is stability: the review literature describes BPC-157 as "resistant to degradation in human gastric juice more than 24 hours" (Sikirić et al., PMC7096228) — unusual for a peptide, and the reason much of the early work explored oral as well as injected routes in animals.

It is the molecule behind several marketing nicknames. Online sellers and wellness clinics often call it the "wolverine peptide," borrowing a comic-book regeneration reputation; we disambiguate that term on a separate page about the so-called wolverine peptide. This monograph is the deeper, evidence-graded write-up that page points to. For how Peptevity assigns the letter grades used below, see our evidence-grading methodology.

A scope note. We cover BPC-157 because it is one of the most-searched and most over-claimed peptides in the recovery and "biohacking" space, and the subject of an active gray-market trade — squarely our editorial lane. We do not sell it, source it, or tell anyone how to use it. Throughout, the governing distinction is species: a finding in a rat is reported as a finding in a rat, never as a human result.

Mechanism of action (Grade D — mechanistic / animal and in-vitro)

The proposed mechanisms are biologically interesting and largely consistent across the preclinical literature. Almost all of them are demonstrated in animals or cell culture, not in human outcome trials. We therefore grade the mechanism claims D (mechanistic / in-vitro) even where a downstream tissue claim is graded higher.

  • Cytoprotection and "organoprotection." The foundational framing extends the classical theory of gastric cytoprotection beyond the stomach. The review literature describes a "stomach cytoprotection → organoprotection" concept, in which protection generalizes "from stomach epithelia to other epithelia … i.e., skin, liver, pancreas, heart" (Sikirić et al., PMC7096228). This is the conceptual core of the whole BPC-157 program.
  • Nitric oxide (NO) system. A recurring proposed mechanism is interaction with the NO pathway. The authors report that BPC-157 "may modulate NO-system effect" and could "override the effects of NOS-blockade … NOS-overstimulation … or NOS-system immobilization" in animal models (Sikirić et al., PMC7096228).
  • Angiogenesis and vascular rescue. BPC-157 is reported to promote angiogenesis. A 2025 review describes it enhancing "vascular endothelial growth factor receptor-2 (VEGFR2) activity and nitric oxide (NO) signaling primarily through activation of the Akt-endothelial nitric oxide synthase (eNOS) pathway," and increasing "ERK1/2 phosphorylation in a dose-dependent manner, leading to increased cellular proliferation, migration, and vascular tube formation" in endothelial cells (PMC12446177). The Zagreb work additionally describes a vascular "rescue" effect during injury — "vessel recruitment to circumvent the vessel occlusion," creating "additional shunting and rapid bypassing loops" (Sikirić et al., PMC7096228).
  • Tendon and fibroblast signaling, growth factors. In tendon and ligament models the proposed pathway is "enhanced fibroblast proliferation and collagen synthesis, primarily via focal adhesion kinase (FAK)-paxillin signaling," accompanied by increased "growth hormone receptor (GHR) expression in fibroblasts" (PMC12446177). This is the mechanistic basis usually invoked for the tendon-healing claims.
  • Neurotransmitter systems. Animal work also reports modulation of "serotonergic and dopaminergic systems," with peripheral administration influencing central effects in stress and toxin models (Sikirić et al., PMC7096228).

The mechanistic story is coherent and explains why researchers expected tissue-repair benefit. What it does not do, on its own, is demonstrate that benefit in a living person. A plausible pathway in a cell or a rat is a hypothesis about humans, not a result in them — the distinction at the center of our explainer on animal versus human peptide evidence.

The evidence, by claim and species

Tendon, ligament, muscle, and bone healing — Grade C (animal-only)

This is the source of BPC-157's recovery reputation, and it is almost entirely preclinical. Predominantly in rats, BPC-157 has been associated with faster healing across multiple musculoskeletal injury models (PMC8275860).

  • Tendon and ligament. Rodent models of transected Achilles tendon and damaged medial collateral ligament report accelerated repair, attributed to the fibroblast/FAK-paxillin pathway above (PMC12446177).
  • Skeletal muscle. "In rodent models, BPC-157 significantly enhances myogenesis, muscle fiber regeneration, and functional recovery post-injury in skeletal muscle" (PMC12446177).
  • Bone. Animal fracture-healing and osteonecrosis models are reported among the musculoskeletal applications (PMC12446177).

The scale of this literature, and its imbalance, is captured by a 2025 systematic review in orthopaedic sports medicine, which identified 35 preclinical (animal) studies and only one clinical study across all musculoskeletal applications of BPC-157 (Vasireddi et al., HSS Journal, 2025, PMC12313605). That same review noted that essentially every published study reported positive effects — a pattern that raises the possibility of publication bias and is a reason to read the animal literature cautiously rather than as a settled result. These are animal findings. The accurate phrasing is "in a rat model, BPC-157 was associated with faster tendon healing," never "BPC-157 heals tendons" — consistent with our editorial standards.

Gut and gastrointestinal protection — Grade C (animal-only)

The compound's origin is gastrointestinal, and so is a large share of its preclinical record. Animal models report protection and faster healing of the stomach and intestinal mucosa, including in ulcer, inflammatory, and anastomosis (surgical-join) models, consistent with the cytoprotection-to-organoprotection framing (Sikirić et al., PMC7096228; PMC8275860). Popular "leaky gut" claims draw on this body of work and on the vascular-rescue idea. They remain animal-grade: there is no qualifying human trial showing BPC-157 treats a gastrointestinal condition in people in the literature we rely on.

Other organ and tissue models — Grade C–D (animal and mechanistic)

The preclinical literature is broad: animal models of corneal injury, spinal cord injury, and various cardiovascular and neurological insults are reported, again predominantly in rats and mice (PMC12446177; Sikirić et al., PMC7096228). Breadth is not the same as depth of evidence. Each of these is an animal or mechanistic signal, and none has been confirmed in a human outcome trial.

Human evidence — Grade C (three small pilots, no RCTs)

This is the part the recovery marketing hides. A 2025 narrative review found that, to the authors' knowledge, only three human studies of BPC-157 have been published, all small pilots, and that no randomized controlled trials exist in humans (PMC12446177). The three, as the review characterizes them:

  • Intra-articular knee injections (Lee & Padgett, 2021). A small case series in which 14 of 16 patients receiving injections containing BPC-157 reported pain relief. Uncontrolled, no comparator (PMC12446177).
  • Interstitial cystitis (Lee et al., 2024). Twelve individuals received intravesical (bladder) injections, with reported symptom resolution at six weeks. Again small and uncontrolled (PMC12446177).
  • Intravenous pharmacokinetics (Lee & Burgess, 2025). Two healthy adults received intravenous infusions (up to 20 mg); the review reports it was well tolerated with plasma concentrations returning to baseline within 24 hours. This is a tiny pharmacokinetic/safety pilot, not an efficacy trial (PMC12446177).

Stated plainly: there is no human RCT establishing that BPC-157 heals tendons, ligaments, muscle, bone, or the gut in people as of this review date. The narrative review's own language is that "rigorous, large-scale trials are lacking" and "well-designed clinical trials are lacking" (PMC12446177). A robust animal literature can sit alongside an almost-empty human shelf — and that is exactly the situation here. We grade the human efficacy claim C: a direction of evidence exists, but it is preliminary, uncontrolled, and thin.

Safety

Safety and evidence grade are separate axes (see our evidence-grading methodology). A compound can have reassuring animal toxicology and still have an essentially uncharacterized human safety profile — which is BPC-157's situation.

  • Human pilots. Across the three small human studies, the reported safety profile was "promising," with no reported side effects (PMC12446177). With samples of roughly 2, 12, and 14–16 participants and no controls, these cannot characterize a human safety profile, only the absence of obvious acute harm in a handful of people.
  • Animal toxicology. Preclinical safety assessments describe BPC-157 as well tolerated at high doses, with researchers reportedly unable to identify a minimum toxic or lethal dose and reporting "no teratogenic, genotoxic, anaphylactic, or local toxic effects" in animal models (PMC12446177). Reassuring in animals; not a substitute for human safety data.
  • Theoretical cautions. Reviewers note proposed risks discussed on mechanistic grounds — for example, that a strongly pro-angiogenic agent could in principle promote pathological angiogenesis or NO overproduction — while also noting BPC-157 has been reported to inhibit uncontrolled cell proliferation in some models (PMC12446177). These are unsettled questions, not established human harms.
  • Regulator concerns. The FDA cited concerns including immunogenicity and peptide-related impurity risks, alongside insufficient human safety data, when it classified BPC-157 in Category 2 in 2023 (FDA). The DoD OPSS advisory adds that products sold as research chemicals carry quality and contamination concerns and warns there is little reliable evidence to support BPC-157's safety or effectiveness in humans (DoD OPSS).

We do not issue a blanket "just don't," and we do not pretend the animal toxicology resolves the question. The honest picture: animal toxicology is reassuring, the three human pilots reported no adverse effects, and yet the human safety profile is essentially unstudied while regulators have flagged immunogenicity and product-quality unknowns. Peptevity publishes no dosing or self-administration instructions for any compound.

The standing Regulatory status block above carries the dated summary; this section explains the nuance, because BPC-157's compounding lane has moved repeatedly.

  • It is not an FDA-approved drug. No BPC-157 product is approved to treat, cure, or prevent any condition. Vendor pages making such claims are making unapproved drug claims.
  • Category 2 listing (2023). In September 2023 the FDA placed BPC-157 in Category 2 of its 503A interim policy — bulk drug substances that "may present significant safety risks" — citing concerns including immunogenicity and peptide-related impurities and a lack of sufficient human safety data (FDA).
  • April 2026 removal — not approval. On 2026-04-15 the FDA announced it was removing BPC-157 (among other peptides) from the interim Category 2 list, effective on or about 2026-04-22, after the nominations supporting the listing were withdrawn. This is a procedural change, not a finding that the safety questions were resolved, and not authorization to compound (Federal Register notice published 2026-04-16; docket FDA-2025-N-6895).
  • July 2026 PCAC review — the live question. BPC-157 is scheduled for a Pharmacy Compounding Advisory Committee review on July 23–24, 2026 at FDA White Oak, where the agency considers whether to move it toward the 503A Category 1 bulks list. The same hearing covers TB-500, KPV, MOTS-c, DSIP (emideltide), epitalon, and Semax; it does not cover GHK-Cu or Melanotan II, which fall in a separate review group expected before the end of February 2027 (FDA PCAC calendar).
  • Research-grade = "RUO." Material sold online is labeled "research use only — not for human consumption." That label is a legal category, not a wink. For the broader framing, see our notes on what "research use only" means and whether peptides are legal, plus the distinction between investigational and approved status.
  • Anti-doping. WADA prohibits BPC-157 at all times under section S0 (Non-Approved Substances) (WADA).

Because this lane shifts, the date matters. We review this page on the same cadence as our living 2026 regulatory tracker, which is our status source-of-record; if the July PCAC review changes the picture, this monograph is updated and the change is logged under our corrections policy.

Honest bottom line

BPC-157 is one of the most heavily studied peptides in the preclinical recovery space and one of the most over-claimed in the consumer one. Tissue healing — tendon, ligament, muscle, bone, and gut — is animal-grade (Grade C), built on roughly 35 preclinical studies, mostly in rats, against a single clinical study and three small, uncontrolled human pilots; there are no human randomized controlled trials (PMC12446177; PMC12313605). The mechanisms — nitric oxide signaling, angiogenesis and VEGFR2, FAK-paxillin fibroblast effects, growth-factor modulation — are plausible and mostly demonstrated in animals and cells (Grade D). Animal toxicology is reassuring and the human pilots reported no adverse effects, but the human safety profile is essentially unstudied, and the FDA has flagged immunogenicity and impurity concerns. It is not an FDA-approved drug; it was listed in Category 2 in 2023, removed in April 2026 (removal is not approval), and faces a PCAC review in July 2026. If you read one thing into this page, read the gap between the substantial rat literature and the near-empty human one — and treat the "heals like a superhero" marketing as exactly the Grade-E claim it is.

For the neighboring compound most often paired with BPC-157, see the TB-500 monograph, the head-to-head BPC-157 vs TB-500 comparison, and — for where the same animal-vs-human gap recurs — the GHK-Cu copper-peptide monograph and the category overview of peptides for health and longevity. For the safety framing across the catalog, see are peptides safe.

Frequently asked questions

What is BPC-157? BPC-157 (body protection compound 157) is a synthetic 15-amino-acid peptide based on a partial sequence reported in mammalian gastric juice, first described in 1993 by Sikirić and colleagues at the University of Zagreb (PMC7096228). It is studied as a cytoprotective agent and is the molecule behind nicknames such as the "wolverine peptide."

Does BPC-157 actually heal tendons, muscle, or the gut? The healing findings come overwhelmingly from animal studies, mostly in rats, where BPC-157 was associated with faster repair of tendon, ligament, muscle, bone, and gut tissue (PMC8275860). A 2025 narrative review found only three small human pilot studies and no randomized controlled trials in humans (PMC12446177). Animal findings do not reliably transfer to people, so human tendon or gut healing is not an established effect.

How is BPC-157 thought to work? Proposed mechanisms, demonstrated mainly in animals and cell culture, include cytoprotection generalized from the stomach to other organs, modulation of the nitric oxide system, promotion of angiogenesis via VEGFR2 and the Akt-eNOS pathway, and enhanced fibroblast proliferation and collagen synthesis via FAK-paxillin signaling (PMC7096228; PMC12446177). These are mechanistic signals, not proof of human benefit.

Is BPC-157 safe? Animal toxicology has been reassuring and the three small human pilots reported no adverse effects, but with only about 2, 12, and 14–16 participants and no controls, the human safety profile is essentially unstudied (PMC12446177). The FDA cited immunogenicity and impurity concerns when it classified BPC-157 in 2023, and the DoD OPSS warns of product-quality and contamination risks in research-chemical products (FDA; DoD OPSS).

Is BPC-157 legal or FDA-approved? BPC-157 is not FDA-approved for any use. The FDA placed it in Category 2 in September 2023, then removed it from that list in April 2026 after the supporting nominations were withdrawn — removal is not approval — and a PCAC review is scheduled for July 23–24, 2026 (FDA; FDA PCAC). It is prohibited by WADA and is typically sold labeled "research use only — not for human consumption." See the dated 2026 regulatory tracker.

Is BPC-157 the same as the "wolverine peptide"? In practice, yes — "wolverine peptide" is a marketing nickname for BPC-157 (sometimes for a BPC-157 + TB-500 stack). We disambiguate the nickname on our wolverine peptide page; this monograph is the full evidence-graded write-up.

How we graded this page

Every claim above is tied to its strongest primary source and labeled by species, per our evidence-grading methodology and sourcing and citation policy. Peptevity carries no advertising, no affiliate links, and sells nothing — see our conflict-of-interest and funding statement.

Primary sources

Related on Peptevity

External references appear as citations only; none of the cited institutions endorse, review, or are affiliated with Peptevity.

Every claim above is cited inline to a primary source. See how we grade evidence and our sourcing & citation policy.